{
  "ticker": "TTX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971722",
  "id": "02971722",
  "pages": 11,
  "price_sensitive": true,
  "date": "20250723",
  "time": "0845",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250723/pdf/06m1nbnjz36c20.pdf",
  "summary": "### **Tetratherix Limited (ASX: TTX) \u2013 Material Information Summary**  \n\n#### **1. License Agreement with BioOptix Inc.**  \n- Exclusive licensing deal to develop/commercialize ophthalmic viscoelastic device (OVD).  \n- Tetratherix becomes minority shareholder in BioOptix.  \n- BioOptix funds FDA regulatory approvals; Tetratherix to manufacture (minimum 1M units for first 5 years post-commercialization).  \n- Licensing income expected from FY26.  \n\n#### **2. Tutelix FDA Progress (50% JV)**  \n- FDA pre-submission completed; product classified as **Class II** device.  \n- **510(k) clearance on track for FY28**, clinical trial design confirmed.  \n\n#### **3. ASX Listing & Capital Raising**  \n- **IPO raised $25M** (primary capital) at **$2.88/share**, market cap **$145M**.  \n- **Closing cash: $29.3M** (no debt).  \n\n#### **4. Financials (Appendix 4C Highlights)**  \n- **Q4 cash outflow: $3.9M** (IPO costs, R&D).  \n- **Cash balance: $29.3M** (inline with prospectus forecasts).  \n\n#### **5. Near-Term Catalysts**  \n- **Tutelix FIH trial** (Q1/Q2 FY26).  \n- **FDA 510(k) clearances for Tegenix/TegeEOS** (target H2 FY26).  \n- **TetraDerm Phase 2 recruitment** (face/neck incisions).  \n\n**No material information omitted.**",
  "usage": {
    "prompt_tokens": 5306,
    "completion_tokens": 349,
    "total_tokens": 5655,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-22T22:49:35.233680"
}